BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Stock Has Consensus Target Price of $21.11 According to Brokerages

Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) have been given an average recommendation of “Moderate Buy” by the eleven analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $21.11.

A number of brokerages recently weighed in on BBOT. JPMorgan Chase & Co. decreased their price target on shares of BridgeBio Oncology Therapeutics from $25.00 to $23.00 and set an “overweight” rating on the stock in a research note on Friday, September 11th. Morgan Stanley cut their price objective on BridgeBio Oncology Therapeutics to $13.00 and set an “overweight” rating for the company in a research note on Wednesday, October 21st. Wall Street Zen raised BridgeBio Oncology Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, October 17th. Raymond James Financial decreased their target price on BridgeBio Oncology Therapeutics from $24.00 to $22.00 and set an “outperform” rating on the stock in a research report on Wednesday, September 9th. Finally, Canaccord Genuity Group lowered their price target on BridgeBio Oncology Therapeutics from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, September 9th.

BridgeBio Oncology Therapeutics Price Performance

BridgeBio Oncology Therapeutics stock opened at $2.30 on Monday. The company’s fifty day moving average price is $4.59 and its 200 day moving average price is $8.03. BridgeBio Oncology Therapeutics has a 1 year low of $2.22 and a 1 year high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($705.20) earnings per share for the quarter. On average, sell-side analysts predict that BridgeBio Oncology Therapeutics will post -2.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

Large investors have recently modified their holdings of the business. Tidal Investments LLC boosted its position in BridgeBio Oncology Therapeutics by 13.6% during the second quarter. Tidal Investments LLC now owns 93,339 shares of the company’s stock worth $711,000 after acquiring an additional 11,167 shares during the last quarter. Tema ETFs LLC lifted its stake in BridgeBio Oncology Therapeutics by 13.6% in the 2nd quarter. Tema ETFs LLC now owns 93,339 shares of the company’s stock worth $711,000 after purchasing an additional 11,167 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in BridgeBio Oncology Therapeutics in the 3rd quarter worth approximately $63,000. Renaissance Technologies LLC boosted its holdings in shares of BridgeBio Oncology Therapeutics by 37.1% during the 1st quarter. Renaissance Technologies LLC now owns 101,900 shares of the company’s stock worth $912,000 after purchasing an additional 27,600 shares during the last quarter. Finally, Avidity Partners Management LP acquired a new position in shares of BridgeBio Oncology Therapeutics during the 1st quarter worth approximately $392,000. Hedge funds and other institutional investors own 54.89% of the company’s stock.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with genetically driven cancers. The company is part of the broader BridgeBio platform, which supports the development of therapies for diseases linked to well-defined biological targets.

Its oncology programs are centered on small-molecule therapies intended to address cancer-causing genetic alterations, including targets that have historically been difficult to treat.